-
1
-
-
0025202883
-
Hormonal evaluation of the patient with an incidentally discovered adrenal mass
-
Ross N, Aron D. Hormonal evaluation of the patient with an incidentally discovered adrenal mass. N Engl J Med 1990; 323: 1401-5.
-
(1990)
N Engl J Med
, vol.323
, pp. 1401-1405
-
-
Ross, N.1
Aron, D.2
-
2
-
-
0025248241
-
Clinical features of adrenocortical carcinoma, prognostic factors and the effect of mitotane therapy
-
Luton JP, Cerdas S, Billaud L et al. Clinical features of adrenocortical carcinoma, prognostic factors and the effect of mitotane therapy. N Engl J Med 1990; 322: 1195-1202.
-
(1990)
N Engl J Med
, vol.322
, pp. 1195-1202
-
-
Luton, J.P.1
Cerdas, S.2
Billaud, L.3
-
4
-
-
0027273847
-
Adrenocortical carcinoma in children: Clinical aspects and prognosis
-
Sabagga C. Avilla S, Schulz C et al. Adrenocortical carcinoma in children: Clinical aspects and prognosis. J Pediatr Surg 1993; 28: 841-3.
-
(1993)
J Pediatr Surg
, vol.28
, pp. 841-843
-
-
Sabagga, C.1
Avilla, S.2
Schulz, C.3
-
5
-
-
16144366677
-
Corticosurénalomes de l'enfant: Analyse rétrospective de 54 cas
-
Teinturier C, Brugières L, Lemerle J et al. Corticosurénalomes de l'enfant: Analyse rétrospective de 54 cas. Arch Pédiatrie 1996; 3: 235-40.
-
(1996)
Arch Pédiatrie
, vol.3
, pp. 235-240
-
-
Teinturier, C.1
Brugières, L.2
Lemerle, J.3
-
6
-
-
0018835921
-
Complete and incomplete forms of Beckwith-Wiedemann syndrome: Their oncogenic potential
-
Sotelo-Avila C, Gonzalez-Crussi F, Fowler J. Complete and incomplete forms of Beckwith-Wiedemann syndrome: Their oncogenic potential. J Pediatr 1980; 96: 47-50.
-
(1980)
J Pediatr
, vol.96
, pp. 47-50
-
-
Sotelo-Avila, C.1
Gonzalez-Crussi, F.2
Fowler, J.3
-
7
-
-
0025633582
-
Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms
-
Malkin D, Li F, Strong L et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250: 1233-8.
-
(1990)
Science
, vol.250
, pp. 1233-1238
-
-
Malkin, D.1
Li, F.2
Strong, L.3
-
8
-
-
0025897503
-
Recurrent or metasuitic disease in selected patients with adrenocortical carcinoma
-
Jensen J, Pass H, Sindelar W, Norton J. Recurrent or metasuitic disease in selected patients with adrenocortical carcinoma. Arch Surg 1991; 126:457-61.
-
(1991)
Arch Surg
, vol.126
, pp. 457-461
-
-
Jensen, J.1
Pass, H.2
Sindelar, W.3
Norton, J.4
-
9
-
-
0027374133
-
Immunohistochemical study of adrenocortical carcinoma: Predictive value of the D11 monoclonal antibody
-
Tartour E, Caillou B, Tenenbaum F et al. Immunohistochemical study of adrenocortical carcinoma: Predictive value of the D11 monoclonal antibody. Cancer 1993; 72: 3296-303.
-
(1993)
Cancer
, vol.72
, pp. 3296-3303
-
-
Tartour, E.1
Caillou, B.2
Tenenbaum, F.3
-
10
-
-
0021350092
-
Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors
-
Weiss L. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 1984; 8: 163-9.
-
(1984)
Am J Surg Pathol
, vol.8
, pp. 163-169
-
-
Weiss, L.1
-
11
-
-
0024513504
-
Pathologic features of prognostic significance in adrenocortical carcinomas
-
Weiss L, Medeiros J, Vickey A. Pathologic features of prognostic significance in adrenocortical carcinomas. Am J Surg Pathol 1989; 13: 202-6.
-
(1989)
Am J Surg Pathol
, vol.13
, pp. 202-206
-
-
Weiss, L.1
Medeiros, J.2
Vickey, A.3
-
12
-
-
0027455046
-
Hypo-aldosteronism accompanied by normal or elevated mineralocorticosteroid pathway steroid: A marker of adrenal carcinoma
-
Aupetit-Faisant B, Battaglia C. Emeric-Blanchouin N, Legrand J. Hypo-aldosteronism accompanied by normal or elevated mineralocorticosteroid pathway steroid: A marker of adrenal carcinoma. J Clin Endocrinol Metab 1993; 76: 38-43.
-
(1993)
J Clin Endocrinol Metab
, vol.76
, pp. 38-43
-
-
Aupetit-Faisant, B.1
Battaglia, C.2
Emeric-Blanchouin, N.3
Legrand, J.4
-
13
-
-
0029145949
-
Plasma levels of aldosterone versus aldosterone precursors: A french retrospective multicentric study
-
Aupetit-Faisant B, Blanchouin-Emeric N, Tenenbaum F et al. Plasma levels of aldosterone versus aldosterone precursors: A french retrospective multicentric study. J Clin Endocrinol Metab 1995; 80: 2715-21.
-
(1995)
J Clin Endocrinol Metab
, vol.80
, pp. 2715-2721
-
-
Aupetit-Faisant, B.1
Blanchouin-Emeric, N.2
Tenenbaum, F.3
-
14
-
-
0029838924
-
MHC class II expression. A new tool to assess dignity in adrenocortical tumours
-
Marx C. Wolkersdörfer G et al. MHC class II expression. A new tool to assess dignity in adrenocortical tumours. J Clin Endocrinol Metab 1996; 81: 4488-91.
-
(1996)
J Clin Endocrinol Metab
, vol.81
, pp. 4488-4491
-
-
Marx, C.1
Wolkersdörfer, G.2
-
15
-
-
0025127424
-
Two G protein oncogenes in human endocrine tumors
-
Lyons J, Landis C, Harsh G et al. Two G protein oncogenes in human endocrine tumors. Science 1990; 249: 655-9.
-
(1990)
Science
, vol.249
, pp. 655-659
-
-
Lyons, J.1
Landis, C.2
Harsh, G.3
-
16
-
-
0027368204
-
No evidence for oncogenic mutations in guanine nucleotide-binding proteins of human adrenocortical neoplasms
-
Reincke M, Karl M, Travis W, Chrousos G. No evidence for oncogenic mutations in guanine nucleotide-binding proteins of human adrenocortical neoplasms. J Clin Endocrinol Metab 1993; 77: 1419-22.
-
(1993)
J Clin Endocrinol Metab
, vol.77
, pp. 1419-1422
-
-
Reincke, M.1
Karl, M.2
Travis, W.3
Chrousos, G.4
-
17
-
-
0028983355
-
Oncogenic mutations of a Gi2 protein are not determinant for human adrenocortical tumourigenesis
-
Gicquel C, Dib A, Bertagna X et al. Oncogenic mutations of a Gi2 protein are not determinant for human adrenocortical tumourigenesis. Eur J Endocrinol 1995; 133: 166-72.
-
(1995)
Eur J Endocrinol
, vol.133
, pp. 166-172
-
-
Gicquel, C.1
Dib, A.2
Bertagna, X.3
-
18
-
-
0027322205
-
Absent ras gene mutations in human adrenal cortical neoplasms and pheochromocytomas
-
Moul J, Bishoff J, Theune S, Chang E. Absent ras gene mutations in human adrenal cortical neoplasms and pheochromocytomas. J Urol 1993; 149: 1389-94.
-
(1993)
J Urol
, vol.149
, pp. 1389-1394
-
-
Moul, J.1
Bishoff, J.2
Theune, S.3
Chang, E.4
-
19
-
-
0027981498
-
Point mutations of RAS genes in human adrenocortical tumors. Absence in adrenocortical hyperplasia
-
Yashiro T, Hara H, Fulton N et al. Point mutations of RAS genes in human adrenocortical tumors. Absence in adrenocortical hyperplasia. World J Surg 1994; 18: 455-61.
-
(1994)
World J Surg
, vol.18
, pp. 455-461
-
-
Yashiro, T.1
Hara, H.2
Fulton, N.3
-
20
-
-
0024558302
-
Genetic changes in human adrenocortical carcinomas
-
Yano T, Linehan M, Anglard P et al. Genetic changes in human adrenocortical carcinomas. J Natl Cancer Inst 1989; 81: 518-23.
-
(1989)
J Natl Cancer Inst
, vol.81
, pp. 518-523
-
-
Yano, T.1
Linehan, M.2
Anglard, P.3
-
21
-
-
0029115129
-
Recent advances in the pathogenesis of adrenocortical tumours
-
Gicquel C, Bertagna X, Le Bouc Y. Recent advances in the pathogenesis of adrenocortical tumours. Eur J Endocrinol 1995; 133: 133-44.
-
(1995)
Eur J Endocrinol
, vol.133
, pp. 133-144
-
-
Gicquel, C.1
Bertagna, X.2
Le Bouc, Y.3
-
22
-
-
0028177520
-
p53 mutations in human adrenocortical neoplasms: Immunohistochemical and molecular studies
-
Reincke M, Karl M, Travis W et al. p53 mutations in human adrenocortical neoplasms: Immunohistochemical and molecular studies. J Clin Endocrinol Metab 1994; 78: 790-4.
-
(1994)
J Clin Endocrinol Metab
, vol.78
, pp. 790-794
-
-
Reincke, M.1
Karl, M.2
Travis, W.3
-
23
-
-
0028144321
-
Mutations of the p53 gene in human functional adrenal neoplasms
-
Lin S, Lee Y, Tsai J. Mutations of the p53 gene in human functional adrenal neoplasms. J Clin Endocrinol Metab 1994; 78: 483-91.
-
(1994)
J Clin Endocrinol Metab
, vol.78
, pp. 483-491
-
-
Lin, S.1
Lee, Y.2
Tsai, J.3
-
24
-
-
0029014425
-
p53 activates expression of HlC-1, a new candidate tumour suppressor gene on 17p13.3
-
Makos Wales M, Biel M, El Deiry W et al. p53 activates expression of HlC-1, a new candidate tumour suppressor gene on 17p13.3. Nature Med 1995; 1: 570-7.
-
(1995)
Nature Med
, vol.1
, pp. 570-577
-
-
Makos Wales, M.1
Biel, M.2
El Deiry, W.3
-
25
-
-
0027536679
-
The expression of the H-19 and IGF-2 genes during human embryogenesis and placental development
-
Goshen R, Rachmilewitz J, Schneider T et al. The expression of the H-19 and IGF-2 genes during human embryogenesis and placental development. Mol Reprod Dev 1993; 34: 374-9.
-
(1993)
Mol Reprod Dev
, vol.34
, pp. 374-379
-
-
Goshen, R.1
Rachmilewitz, J.2
Schneider, T.3
-
26
-
-
0028326318
-
Parallel regulation of parentally imprinted H19 and insulin-like growth factor II genes in cultured human fetal adrenal cells
-
Voutilainen R, Ilvesmäki V. Ariel I et al. Parallel regulation of parentally imprinted H19 and insulin-like growth factor II genes in cultured human fetal adrenal cells. J Clin Endocrinol Metab 1994; 134: 2051-6.
-
(1994)
J Clin Endocrinol Metab
, vol.134
, pp. 2051-2056
-
-
Voutilainen, R.1
Ilvesmäki, V.2
Ariel, I.3
-
27
-
-
0027370355
-
Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: High IGF-II expression in functional adrenocortical carcinomas
-
Ilvesmäki V, Kahri A, Miettinen P, Voutilainen R. Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: High IGF-II expression in functional adrenocortical carcinomas. J Clin Endocrinol Metab 1993; 77: 852-8.
-
(1993)
J Clin Endocrinol Metab
, vol.77
, pp. 852-858
-
-
Ilvesmäki, V.1
Kahri, A.2
Miettinen, P.3
Voutilainen, R.4
-
28
-
-
0028298220
-
Rearrangements at 11p15 locus and overexpression of insulin like growth factor-II gene in sporadic adrenocortical tumors
-
Gicquel C, Bertagna X, Schneid H et al. Rearrangements at 11p15 locus and overexpression of insulin like growth factor-II gene in sporadic adrenocortical tumors. J Clin Endocrinol Metab 1994; 78: 1444-53.
-
(1994)
J Clin Endocrinol Metab
, vol.78
, pp. 1444-1453
-
-
Gicquel, C.1
Bertagna, X.2
Schneid, H.3
-
29
-
-
0028059816
-
Genetic events in the development of Wilms' tumor
-
Coppes M, Haber D, Grundy P. Genetic events in the development of Wilms' tumor. N Engl J Med 1994; 331: 586-90.
-
(1994)
N Engl J Med
, vol.331
, pp. 586-590
-
-
Coppes, M.1
Haber, D.2
Grundy, P.3
-
30
-
-
0028587166
-
The genetics of Wilms' tumor. A case of disrupted development
-
Hastie N. The genetics of Wilms' tumor. A case of disrupted development. Ann Rev Genet 1994; 28: 523-58.
-
(1994)
Ann Rev Genet
, vol.28
, pp. 523-558
-
-
Hastie, N.1
-
31
-
-
0029939816
-
Somatic overgrowth associated with overexpression of insulin-like growth factor II
-
Morison I, Becroft D, Taniguchi T et al. Somatic overgrowth associated with overexpression of insulin-like growth factor II. Nature Med 1996; 2: 311-6.
-
(1996)
Nature Med
, vol.2
, pp. 311-316
-
-
Morison, I.1
Becroft, D.2
Taniguchi, T.3
-
32
-
-
0028800645
-
Insulin-like growth factors and cancer
-
Le Roith D. Insulin-like growth factors and cancer. Ann Intern Med 1995; 122: 54-9.
-
(1995)
Ann Intern Med
, vol.122
, pp. 54-59
-
-
Le Roith, D.1
-
33
-
-
0025967857
-
Parental imprinting of the mouse insulin-like growth factor II gene
-
De Chiara T, Robertson E, Efstratiadis A. Parental imprinting of the mouse insulin-like growth factor II gene. Cell 1991; 64: 849-59.
-
(1991)
Cell
, vol.64
, pp. 849-859
-
-
De Chiara, T.1
Robertson, E.2
Efstratiadis, A.3
-
34
-
-
0027442239
-
Tumour-suppressor activity of H19 RNA
-
Hao Y, Crenshaw T, Moulton T et al. Tumour-suppressor activity of H19 RNA. Nature 1993; 365: 764-7.
-
(1993)
Nature
, vol.365
, pp. 764-767
-
-
Hao, Y.1
Crenshaw, T.2
Moulton, T.3
-
35
-
-
0028988159
-
p57 K1P2, a structurally distinct member of the p21CIP2 Cdk inhibitor family, is a candidate tumor suppressor gene
-
Matsuoka S, Edwards M, Bai C et al. p57 K1P2, a structurally distinct member of the p21CIP2 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 1995; 9: 650- 62.
-
(1995)
Genes Dev
, vol.9
, pp. 650-662
-
-
Matsuoka, S.1
Edwards, M.2
Bai, C.3
-
36
-
-
0028988158
-
Cloning of p57 KIP2, a cyclin dependent kinase inhibitor with unique domain structure and tissue distribution
-
Mong-Hong L, Reynisdottir I, Massagué J. Cloning of p57 KIP2, a cyclin dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 1995; 9: 639-49.
-
(1995)
Genes Dev
, vol.9
, pp. 639-649
-
-
Mong-Hong, L.1
Reynisdottir, I.2
Massagué, J.3
-
37
-
-
0030226250
-
p57KIP2 is expressed in Wilm's tumor with LOH of 11p15.5
-
Overall M, Spencer J, Bakker M et al. p57KIP2 is expressed in Wilm's tumor with LOH of 11p15.5. Genes Chrom Cancer 1996; 17: 56-9.
-
(1996)
Genes Chrom Cancer
, vol.17
, pp. 56-59
-
-
Overall, M.1
Spencer, J.2
Bakker, M.3
-
38
-
-
0024582517
-
The Cleveland clinic experience with adrenal cortical carcinoma
-
Bodie B, Novick AC, Pontes JE et al. The Cleveland clinic experience with adrenal cortical carcinoma. J Urol 1989; 141: 257-60.
-
(1989)
J Urol
, vol.141
, pp. 257-260
-
-
Bodie, B.1
Novick, A.C.2
Pontes, J.E.3
-
39
-
-
0021044886
-
Adrenal cortical carcinoma. A continuing challenge
-
Henley DJ, Van Heerden JA, Grant CS et al. Adrenal cortical carcinoma. A continuing challenge. Surgery 1983; 94: 926-31.
-
(1983)
Surgery
, vol.94
, pp. 926-931
-
-
Henley, D.J.1
Van Heerden, J.A.2
Grant, C.S.3
-
40
-
-
0027087416
-
Adrenocortical carcinoma in surgically treated patients: A retrospective study on 156 cases by the French Association of Endocrine Surgery
-
Icard P, Chapuis Y, Andreassian B et al. Adrenocortical carcinoma in surgically treated patients: A retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery 1992; 112: 972-80.
-
(1992)
Surgery
, vol.112
, pp. 972-980
-
-
Icard, P.1
Chapuis, Y.2
Andreassian, B.3
-
41
-
-
0027051533
-
An eleven-year experience with adrenocortical carcinoma
-
Pommier RF, Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery 1992; 112: 963-71.
-
(1992)
Surgery
, vol.112
, pp. 963-971
-
-
Pommier, R.F.1
Brennan, M.F.2
-
42
-
-
0021332006
-
Complete response of metastasized adrenal cortical carcinoma with Op'-DDD
-
Boven E, Vermorken JB, Van Slooten H, Pinedo HM. Complete response of metastasized adrenal cortical carcinoma with Op'-DDD. Cancer 1984; 3: 26-9.
-
(1984)
Cancer
, vol.3
, pp. 26-29
-
-
Boven, E.1
Vermorken, J.B.2
Van Slooten, H.3
Pinedo, H.M.4
-
43
-
-
0028208020
-
Optimal treatment of adrenocortical carcinoma with mitotane: Results in a consecutive series of 96 patients
-
Haak HR, Hermans J, Van de Velde CJH et al. Optimal treatment of adrenocortical carcinoma with mitotane: Results in a consecutive series of 96 patients. Br J Cancer 1994; 69: 947-51.
-
(1994)
Br J Cancer
, vol.69
, pp. 947-951
-
-
Haak, H.R.1
Hermans, J.2
Van De Velde, C.J.H.3
-
44
-
-
0023633243
-
The effect of Op'DDD on adrenal steroid replacement therapy requirements
-
Robinson BG, Hales IB, Henniker AJ et al. The effect of Op'DDD on adrenal steroid replacement therapy requirements. Clin Endocrinol 1987; 27: 437-44.
-
(1987)
Clin Endocrinol
, vol.27
, pp. 437-444
-
-
Robinson, B.G.1
Hales, I.B.2
Henniker, A.J.3
-
47
-
-
0019306305
-
Cisplatinum treatment of metaslatic adrenal carcinoma
-
Tattersall MHN, Lander H, Bain B et al. Cisplatinum treatment of metaslatic adrenal carcinoma. Med J Aust 1980; 1: 419-21.
-
(1980)
Med J Aust
, vol.1
, pp. 419-421
-
-
Tattersall, M.H.N.1
Lander, H.2
Bain, B.3
-
48
-
-
0027465121
-
Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: A Southwest Oncology Group Study
-
Bukowski RM, Wolfe M, Levine HS et al. Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: A Southwest Oncology Group Study. J Clin Oncol 1993; 11: 161-5.
-
(1993)
J Clin Oncol
, vol.11
, pp. 161-165
-
-
Bukowski, R.M.1
Wolfe, M.2
Levine, H.S.3
-
49
-
-
0020619434
-
CAP (Cyclophosphamide, Doxorubicin and Cisplatinum) Regimen in adrenal cortical carcinoma
-
Van Slooten H, Van Oosterom AT. CAP (Cyclophosphamide, Doxorubicin and Cisplatinum) Regimen in adrenal cortical carcinoma. Cancer Treat Rep 1983; 67: 377-9.
-
(1983)
Cancer Treat Rep
, vol.67
, pp. 377-379
-
-
Van Slooten, H.1
Van Oosterom, A.T.2
-
50
-
-
0025794205
-
Fluorouracil, Doxorubicin and Cisplatin as treatment for adrenal cortical carcinoma
-
Schlumberger M, Brugieres L, Gicquel C et al. Fluorouracil, Doxorubicin and Cisplatin as treatment for adrenal cortical carcinoma. Cancer 1991; 67: 2997-3000.
-
(1991)
Cancer
, vol.67
, pp. 2997-3000
-
-
Schlumberger, M.1
Brugieres, L.2
Gicquel, C.3
-
51
-
-
0026343069
-
Eastern Cooperative Oncology Group Study 1879: Mitotane and adriamycin in patients with advanced adrenocortical carcinoma
-
Decker RA, Elson P, Hogan TF et al. for the Eastern Cooperative Oncology Group. Eastern Cooperative Oncology Group Study 1879: Mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery 1991; 110: 1006-13.
-
(1991)
Surgery
, vol.110
, pp. 1006-1013
-
-
Decker, R.A.1
Elson, P.2
Hogan, T.F.3
-
52
-
-
0004458012
-
Chemotherapy with cis-platinum and etoposide (VP16) for patients with advanced adrenal cortical carcinoma (ACC)
-
Proc ASCO
-
Burgess MA, Legha SS, Sellin RV. Chemotherapy with cis-platinum and etoposide (VP16) for patients with advanced adrenal cortical carcinoma (ACC). Proc ASCO, J Clin Oncol 1993; 12: 188.
-
(1993)
J Clin Oncol
, vol.12
, pp. 188
-
-
Burgess, M.A.1
Legha, S.S.2
Sellin, R.V.3
-
53
-
-
0025739481
-
Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (MDR-1/P-Glycoprotein) which is also expressed by adrenocortical carcinoma
-
Bates SE, Shieh CY, Mickley LA et al. Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (MDR-1/P-Glycoprotein) which is also expressed by adrenocortical carcinoma. J Clin Endocrinol Metab 1991; 73: 18-29.
-
(1991)
J Clin Endocrinol Metab
, vol.73
, pp. 18-29
-
-
Bates, S.E.1
Shieh, C.Y.2
Mickley, L.A.3
-
54
-
-
0027092727
-
P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma
-
Flynn SD, Murren JR, Kirby WM et al. P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma. Surgery 1992; 112: 981-6.
-
(1992)
Surgery
, vol.112
, pp. 981-986
-
-
Flynn, S.D.1
Murren, J.R.2
Kirby, W.M.3
-
55
-
-
0025079187
-
Suramin in adrenal cancer: Modulation of steroid hormone production. cytotoxicity in vitro, and clinical antitumor effect
-
La Rocca RV, Stein CA, Danesi R et al. Suramin in adrenal cancer: Modulation of steroid hormone production. cytotoxicity in vitro, and clinical antitumor effect. J Clin Endocrinol Metab 1990; 71: 497-504.
-
(1990)
J Clin Endocrinol Metab
, vol.71
, pp. 497-504
-
-
La Rocca, R.V.1
Stein, C.A.2
Danesi, R.3
-
56
-
-
0028075055
-
Suramin in adrenocortical cancer: Limited efficacy and serious toxicity
-
ArIt W, Reincke M, Siekmann L et al. Suramin in adrenocortical cancer: Limited efficacy and serious toxicity. Clin Endocrinol 1994; 41: 299-307.
-
(1994)
Clin Endocrinol
, vol.41
, pp. 299-307
-
-
Arit, W.1
Reincke, M.2
Siekmann, L.3
-
57
-
-
0026337882
-
Suramin and the human adrenocortex: Results of experimental and clinical studies
-
Dorfinger K, Niederle B, Vierhapper H et al. Suramin and the human adrenocortex: Results of experimental and clinical studies. Surgery 1991; 100: 1100-5.
-
(1991)
Surgery
, vol.100
, pp. 1100-1105
-
-
Dorfinger, K.1
Niederle, B.2
Vierhapper, H.3
|